Cancer medicine · 2026
Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Price Claire A, Cooke Debbie, Mold Freda, Smith Nadia A S, Winn Martyn, Lemanska Agnieszka
Аннотация
INTRODUCTION: Pancreatic cancer has a high mortality rate due to late diagnosis and presentation with non-specific symptoms like weight loss. Quantifying weight loss more precisely could enhance its utility as a diagnostic marker.
METHODS: In March 2025, we systematically searched PubMed, Embase, Web of Science, The Cochrane Library, and Scopus for studies reporting quantitative pre-diagnosis weight loss in pancreatic cancer, with no date restrictions. The protocol was registered with PROSPERO (CRD42022302985). Primary outcomes were weight loss (kg) and BMI change (kg/m2). Meta-analyses provided pooled estimates with 95% confidence intervals, displayed in forest plots. We conducted stratified analyses at the study level by diabetes status, cancer type, self-reported weight change, and timing of weight loss. Subgroup analyses considered publication year, country, study design, mean age, and percentage of male participants. Study quality and bias were assessed using the ROBINS-I framework.
RESULTS: The analysis included 25 studies (25,971 participants). In random-effects meta-analysis, we found that on average participants lost 5.9 kg [95% CI 4.7 to 7.1] of body weight. The average BMI change was -2.5 kg/m2 [95% CI -3.0 to -2.1]. There was significant heterogeneity between studies for both weight loss (I2 = 99.2%) and BMI change (I2 = 82.6%). For weight loss in kg, heterogeneity was partially explained (p < 0.001) by diabetes status (0.15%), weight loss timing (15.5%), whether weight loss was self-reported (11.4%) and publication year (13.1%). For BMI change heterogeneity was partially explained (p < 0.001) by pancreatic cancer type (1.3%), whether BMI change was self-reported (49.6%) and publication year (49.5%). Post hoc pairwise comparisons of moderators for stratified analysis were not significant (p < 0.0125). The certainty of evidence was moderate due to high heterogeneity between studies.
CONCLUSIONS: This meta-analysis provides a reference for expected weight loss in pancreatic cancer, aiding clinical practice and improving early detection models.
METHODS: In March 2025, we systematically searched PubMed, Embase, Web of Science, The Cochrane Library, and Scopus for studies reporting quantitative pre-diagnosis weight loss in pancreatic cancer, with no date restrictions. The protocol was registered with PROSPERO (CRD42022302985). Primary outcomes were weight loss (kg) and BMI change (kg/m2). Meta-analyses provided pooled estimates with 95% confidence intervals, displayed in forest plots. We conducted stratified analyses at the study level by diabetes status, cancer type, self-reported weight change, and timing of weight loss. Subgroup analyses considered publication year, country, study design, mean age, and percentage of male participants. Study quality and bias were assessed using the ROBINS-I framework.
RESULTS: The analysis included 25 studies (25,971 participants). In random-effects meta-analysis, we found that on average participants lost 5.9 kg [95% CI 4.7 to 7.1] of body weight. The average BMI change was -2.5 kg/m2 [95% CI -3.0 to -2.1]. There was significant heterogeneity between studies for both weight loss (I2 = 99.2%) and BMI change (I2 = 82.6%). For weight loss in kg, heterogeneity was partially explained (p < 0.001) by diabetes status (0.15%), weight loss timing (15.5%), whether weight loss was self-reported (11.4%) and publication year (13.1%). For BMI change heterogeneity was partially explained (p < 0.001) by pancreatic cancer type (1.3%), whether BMI change was self-reported (49.6%) and publication year (49.5%). Post hoc pairwise comparisons of moderators for stratified analysis were not significant (p < 0.0125). The certainty of evidence was moderate due to high heterogeneity between studies.
CONCLUSIONS: This meta-analysis provides a reference for expected weight loss in pancreatic cancer, aiding clinical practice and improving early detection models.